SLE Management Guidelines

Initial Treatment and Monitoring

The American College of Rheumatology recommends hydroxychloroquine 200-400 mg daily (≤5 mg/kg actual body weight) for all patients with SLE, unless contraindicated, to reduce flares, organ damage, and mortality 1
Glucocorticoids should be minimized from the outset, with oral prednisone 0.3-0.5 mg/kg/day (never exceed 1 mg/kg/day or 60 mg/day), and aggressively taper to ≤7.5 mg/day within 3-6 months 2, 1
Immunosuppressive agents, such as mycophenolate mofetil, azathioprine, or methotrexate, should be added early to facilitate glucocorticoid tapering and maintain disease control 1

For Lupus Nephritis (Class III-IV), first-line induction treatment is mycophenolate mofetil 2-3 g/day or low-dose IV cyclophosphamide, with pulse IV methylprednisolone 500-2500 mg total, followed by oral prednisone 0.3-0.5 mg/kg/day 2, 1
The target for Lupus Nephritis treatment is proteinuria <0.5-0.7 g/24h by 12 months, with ≥50% reduction by 6 months 2

At diagnosis, obtain a complete autoantibody panel and complement levels to establish a serologic baseline, including ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm, and antiphospholipid antibodies 4
Renal function should be monitored with serum creatinine, urinalysis with microscopy, and urine protein-to-creatinine ratio 2, 4
Hematology should be monitored with a complete blood count with differential, and infection screening should include HIV, hepatitis B/C, and tuberculosis screening before immunosuppression 4

Hydroxychloroquine requires ophthalmologic examination annually after 5 years of treatment, and consideration of blood level monitoring (target >0.6 mg/L) to minimize retinal toxicity risk 5
Cyclophosphamide requires counseling on gonadal toxicity and fertility preservation before initiating, and monitoring of serum creatinine and drug blood levels to avoid chronic nephrotoxicity 3, 1

Never delay immunosuppressive therapy, as glucocorticoids alone are insufficient for organ-threatening disease and lead to prolonged high-dose steroid exposure with accelerated damage accrual 3
Avoid premature treatment changes, as proteinuria decreases slowly, especially with nephrotic-range baseline, and allow 6-12 months for response assessment 2
Aggressively exclude infection before intensifying immunosuppression, particularly in patients with severe neutropenia, lymphopenia, or hypogammaglobulinemia, and administer inactivated vaccines when disease is inactive 4, 3